Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1753 participants.
Also called NCT03969953
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,753 participants
- Sponsor
- Registry
-
NCT03969953
-
- Other papers using this trial's data
- Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Belgium, Canada, France, Germany, India, Malaysia, Nepal, Saudi Arabia, Singapore, Taiwan, Tunisia
- Registry status
- Completed
Technical summary
Registry record NCT03969953. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-18 (actual); primary completion 2025-10-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
- Acronym
- TRACK
- Condition
- Chronic Kidney Diseases
- Condition
- Dialysis-dependent Kidney Failure
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- Rivaroxaban 2.5 Mg Oral Tablet
- Intervention (Other)
- Placebo
- Lead sponsor
- The George Institute
- Collaborator
- Emerald Clinical Inc.
- Collaborator
- Bayer
- Collaborator
- Central Hospital, Nancy, France
- Collaborator
- King Abdullah International Medical Research Center
Record details
- Record id
cardio:ct-nct03969953- Content hash
efc765b15acbdb97f628bc54ef28a7443d91b13d601327fdfad17b25eed11178